Clinical trials: multiple sclerosis
Multiple Sclerosis (MS), Neurogenic Bladder Disorder
Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients
The goal of this clinical trial is to learn if essential oil aromatherapy works to improve urinary symptoms in adults with multiple sclerosis. It will also learn about the safety of essential oil use in this population.
- Conditions
- Multiple Sclerosis (MS), Neurogenic Bladder Disorder, Urinary Incontinence (UI), Urinary Urgency
- Trial name
- AROMA-MS (NCT07599189)
- Testing
- Essential Oil Blend (Lavender, Rosemary), Neutral Carrier Oil (Apricot Kernel Oil)
- Where
- 2 sites in Algeria
- Volunteers
- 60 people
- Sponsor
- University of Oran 1
Relapsing Remitting Multiple Sclerosis
A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
The purpose of this study is to compare biomarker levels in Multiple Sclerosis (MS) patients before and after beginning Natalizumab.
- Trial name
- NCT01541618
- Testing
- MSDX Complex-1 Biomarker test
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- MSDx, Inc.
Multiple Sclerosis
Study to Evaluate the Reliability and Validity of the Modified Manual Muscle Test for Persons With MS
Many patients with multiple sclerosis (MS) are treated with physiotherapy. Muscle weakness is a common symptom. It can be evaluated with a variety of muscle function tests.
- Trial name
- NCT03603691
- Testing
- Modified Manual Muscle Test, BMRC manual muscle test, MicroFET2 handhold dynamometer
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- Nanco van der Maas
Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset
Newly diagnosed relapsing multiple sclerosis (MS) and high risk clinically isolated syndrome (CIS) patients will be treated with ocrelizumab at disease onset to see if treatment favorably alters CSF markers of chronic…
- Trial name
- IMPACT MS (NCT04466150)
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Multiple Sclerosis
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
- Trial name
- TRANSFORMS (NCT00340834)
- Testing
- Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 1,292 people
- Sponsor
- Novartis
Multiple Sclerosis
Low Fat Diet and Multiple Sclerosis
The purpose of this study is to evaluate if following a specific low fat diet will improve the brain damage as seen by Magnetic Resonance Imaging (MRI) and to decrease the progression of multiple sclerosis (MS) as evidenced by…
- Trial name
- MS (NCT00852722)
- Testing
- Low fat study diet
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Oregon Health and Science University
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS)
Objective: The primary goal of this study is to investigate the mechanism of action (MOA) of CD25-blocking therapies in high inflammatory multiple sclerosis (HI-MS).
- Trial name
- NCT01143441
- Testing
- DAC-HYP
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis
Validation and Standardization of Paramagnetic Rim Lesion (PRL) Identification in Multiple Sclerosis Across MAGNIMS Centers
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system. Paramagnetic rim lesions (PRLs) are a subtype of chronic active MS lesions showing an iron-laden inflammatory rim on…
- Trial name
- NCT07705581
- Where
- 15 sites in Austria, Czechia and 9 more
- Volunteers
- 1,402 people
- Sponsor
- IRCCS San Raffaele
Multiple Sclerosis
Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis
The primary objective was to estimate the tolerability and safety of 2 doses of Teriflunomide administered once daily for 24 weeks, compared to placebo, in patients with multiple sclerosis [MS] with relapses who were on a stable…
- Trial name
- NCT00475865
- Testing
- Teriflunomide, Glatiramer Acetate (GA)
- Where
- 6 sites in United States, Austria and 4 more
- Volunteers
- 123 people
- Sponsor
- Sanofi
Multiple Sclerosis
A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months
To explore whether treatment with glatiramer acetate (GA) may decrease iron deposition in subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months and compared to a reference population…
- Trial name
- GASWI (NCT01695434)
- Testing
- MRI
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Relapsing Multiple Sclerosis
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
The primary objective of this study is to determine the efficacy of peginterferon beta-1a in reducing the annualized relapse rate (ARR) in participants with relapsing multiple sclerosis (RMS) at 1 year.
- Trial name
- ADVANCE (NCT00906399)
- Testing
- BIIB017 (peginterferon beta-1a)
- Where
- 178 sites in United States, Belgium and 24 more
- Volunteers
- 1,516 people
- Sponsor
- Biogen
Fatigue in Multiple Sclerosis
Testing the Effects of Methylphenidate on Multiple Sclerosis
Up to 95% of individuals with Multiple Sclerosis report experiencing cognitive fatigue, characterized by a lack of energy, feelings of exhaustion, an the perception that one is unable to partake in daily activities.
- Trial name
- NCT02286557
- Testing
- Methelphenidate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Kessler Foundation
Multiple Sclerosis
IL-2 Signaling and Polarization of Regulatory LBs: Involvement in Multiple Sclerosis
Multiple sclerosis (MS) has long been considered a disease mediated primarily by CD4+ T cells. However, recent clinical trials demonstrating significant efficacy of B-lymphocyte depletive therapies have highlighted the major role…
- Trial name
- BREGS (NCT04697407)
- Testing
- Blood sampling, CSF sampling
- Where
- France
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- Rennes University Hospital
Multiple Sclerosis
Structured Exercise Training in Newly Diagnosed Multiple Sclerosis
the effectiveness of structured exercise training will be investigated for individuals with MS who are newly diagnosed and have no clinical problems.
- Trial name
- NCT05957809
- Testing
- Structured exercise training
- Where
- Turkey (Türkiye)
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Multiple Sclerosis
Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS
This study evaluates the effects of sustained-release oral dalfampridine in the treatment of upper limb deficits in people with multiple sclerosis (MS).
- Trial name
- NCT02259361
- Testing
- Sustained-release oral dalfampridine
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Sheba Medical Center
Multiple Sclerosis
Validation of Multimodal Evoked Potentials (mmEP) for Predicting Disease Progression in Multiple Sclerosis
Utility of Multimodal Evoked potentials (mmEP) for monitoring disease course and prediction of progression at different stages of Multiple Sclerosis (MS) is investigated
- Trial name
- SMSC (NCT03632473)
- Testing
- multimodal evoked potentials (mmEP)
- Where
- 3 sites in Switzerland
- Volunteers
- 29 people
- Sponsor
- University Hospital, Basel, Switzerland
Multiple Sclerosis
Safety of Switching From Rituximab to Ocrelizumab in MS Patients
This is a prospective between and within group observational study to determine differences in tolerability, immunogenicity and safety related outcomes for 100 multiple sclerosis (MS) patients who have been administered at least…
- Trial name
- NCT02980042
- Testing
- Ocrelizumab, Rituximab
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis
Ischemic Preconditioning, Exercise Tolerance and Multiple Sclerosis
Regular physical activity improves aspects such as physical fitness, fatigue, quality of life, gait and also reduces the rate of progression of disability in individuals with Multiple Sclerosis.
- Trial name
- NCT03153553
- Testing
- Ischemic Preconditioning
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
ALS
Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis
The primary objective of this study is to assess the safety and tolerability, with emphasis on the oral cavity, of ROSF (containing riluzole 50mg) in subjects with amyotrophic lateral sclerosis (ALS) administered twice daily for…
- Trial name
- NCT03457753
- Testing
- Riluzole Oral Soluble Film
- Where
- United States
- Sponsor
- Aquestive Therapeutics
Multiple Sclerosis, MS
Vista Protein Expression of Monocyte and T Cell Subsets in Multiple Sclerosis and Its Clinical Correlation
The aim of this study is to investigate whether VISTA, a newly identified negative immune regulatory protein, differs in monocytes and T cells of patients diagnosed with Multiple Sclerosis (MS) and Clinically Isolated Syndrome…
- Trial name
- NCT06957145
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Koç University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.